anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open-label, multicenter study of oral azacitidine in MDS or AML patients who have undergone allogeneic HSCT. The study consists of three phases: Screening, Treatment and Follow-up. During the Screening phase, the study doctor will do tests to see if the patient is suitable for this study. The patients meeting protocol-specified entry criteria will enter the treatment phase and be assigned to receive one of the oral azacitidine cohorts. The dosing group of 200 mg QD on Days 1 to 7 will be evaluated first (ie, Cohort 1). In the event that unacceptable toxicity occurs in Cohort 1, then oral azacitidine may be evaluated at lower dose levels (eg, 150 mg). If the dosing regimen is confirmed to be safe in Cohort 1, other cohorts will be evaluated sequentially. During the treatment phase, patients will be monitored closely for safety and tolerability. Dosing interruption or delay, dose or schedule reduction, intra-subject dose/schedule escalation or re-escalation may occur on the basis of protocol-specified dosing adjustment guidelines. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by vital signs, physical examination, performance status, laboratory tests and evaluation of adverse events. The patient can continue to receive the study treatment for up to 12 months provided that they benefit from the study treatment and all protocol-specified criteria are met. However, the patient may receive the study treatment for less than 12 months due to adverse event, disease recurrence or progression. When the study treatment is discontinued, all patients who have received at least one dose of oral azacitidine will be asked to see the study doctor for the treatment discontinuation visit. Thereafter, all patients discontinued from the study treatment will enter the Follow-up phase for safety and survival follow up.
PURPOSE:To provide a drug delivery member having the adhesivity to the skin, the drug releasability, the rapid action, etc. as a pressure-sensitive adhesive, by compounding a water-insoluble polymer having stickiness at normal temperature with a specific water-soluble polymer, water, and a drug for transcutaneous absorption. CONSTITUTION:A water-insoluble polymer having stickiness at normal temperature (e.g. natural rubber, synthetic rubber, acrylic polymer, etc.) is compounded with a water-soluble polymer composed of a monomer having one ethylenic unsaturated double bond [e.g. PVA, poly(meth)acrylic acid, etc.] and/or a polysaccharide (e.g. starch, pullullan, etc.), water, and a drug for transcutaneous absorption (e.g. corticosteroid, analgesic antiinflammatory agent, etc.). The obtained pressure-sensitive adhesive layer is applied to a carrier to obtain the objective drug delivery member. An excellent drug action can be exhibited by the action of the water-soluble polymer, the polysaccharide and water to impart the adhesive layer with the characteristics of an aqueous gel, i.e. skin moisturizing effect, drug-releasing property, adhesivity, etc.
BACKGROUND: Ankle muscle strength should be assessed after a lateral ankle sprain (LAS) because a strength deficit can lead to chronic ankle instability (CAI). No field method is available to obtain quantitative ankle dynamic strength values. This study aimed to assess the reliability of the one-repetition maximal (1-RM) method and to compare ankle muscle strength between healthy volunteers and those with CAI using 1-RM strength assessment approach.
METHODS: We recruited 31 healthy volunteers and 32 with CAI. Dorsiflexor, evertor, and invertor 1-RM were performed twice at a one-week interval. The intraclass correlation coefficient (ICC) and minimal detectable change (MDC) were calculated. Strength values were compared between healthy volunteers and CAI.
RESULTS: The 1-RM method is reliable for assessing ankle dorsiflexor, evertor, and invertor strength, with an ICC ranging from 0.76 to 0.88, and MDC ranging from 19 to 31%. Volunteers with CAI obtained evertor (3.0 vs. 3.5 N/kg), invertor (2.9 vs. 3.7 N/kg), and dorsiflexor (5.9 vs. 6.5 N/kg) strength values that were lower than healthy volunteers (p < 0.05).
CONCLUSION: The 1-RM test can be used in practice to assess evertor, invertor, and dorsiflexor strength during the rehabilitation of LAS. This field method could help practitioners to detect a strength deficit and individualize a strengthening programme if necessary.
This invention comprises an unpleasant-taste-masked pharmaceutical composition for oral consumption comprising at least one pharmaceutical active compound of unpleasant taste; the said pharmaceutical composition comprising an agglomerate of the pharmaceutically active compound/s, at least one sweetener and optionally one or more of diluents/bulking agents, excipients/adjuvents and flavors. In one embodiment of the unpleasant-taste-masked pharmaceutical composition, the sweetener in the agglomerate comprises at least a high intensity sweetener; or a mixture of one or more of low intensity sweetener and at least one high intensity sweetener. An embodiment of the unpleasant-taste-masked pharmaceutical composition may further comprise a coating of a water insoluble material on the agglomerate wherein the thickness of the coating is strong enough to prevent release of unpleasant taste on tongue when orally administered but release more than 80% of the pharmaceutically active unpleasant tasting compound in 15 minutes when subjected to dissolution in Phosphate buffer pH 5.8 media using USP Type 2 apparatus. The unpleasant-taste-masked pharmaceutical composition of this invention may further comprise at least one thickener in the agglomerate. The unpleasant-taste-masked pharmaceutical composition of this invention may also comprise at least one binding agent in the agglomerate or/and may also comprise effervescence generating means. In the context of this invention, unpleasant taste comprises bitter taste and any other taste that is repulsive for oral consumption. The pharmaceutical composition of this invention may be an orodispersible or water dispersible composition. The invention also comprises methods of making the compositions of this invention.
In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. To ensure preload, TEE will be used to monitor LVEDV and SV.
BACKGROUND: Nutritional administration in acute pancreatitis (AP) management has sparked widespread discussion, yet contradictory mortality results across meta-analyses necessitate clarification. The optimal nutritional route in AP remains uncertain. Therefore, this study aimed to compare mortality among nutritional administration routes in patients with AP using consistency model.
METHODS: This study searched four major databases for relevant randomized controlled trials (RCTs). Two authors independently extracted and checked data and quality. Network meta-analysis was conducted for estimating risk ratios (RRs) with 95% confidence interval (CI) based on random-effects model. Subgroup analyses accounted for AP severity and nutrition support initiation.
RESULTS: A meticulous search yielded 1185 references, with 30 records meeting inclusion criteria from 27 RCTs (n = 1594). Pooled analyses showed the mortality risk reduction associated with nasogastric (NG) (RR = 0.34; 95%CI: 0.16-0.73) and nasojejunal (NJ) feeding (RR = 0.46; 95%CI: 0.25-0.84) in comparison to nil per os. Similarly, NG (RR = 0.45; 95%CI: 0.24-0.83) and NJ (RR = 0.60; 95%CI: 0.40-0.90) feeding also showed lower mortality risk than total parenteral nutrition. Subgroup analyses, stratified by severity, supported these findings. Notably, the timing of nutritional support initiation emerged as a significant factor, with NJ feeding demonstrating notable mortality reduction within 24 and 48 h, particularly in severe cases.
CONCLUSION: For severe AP, both NG and NJ feeding appear optimal, with variations in initiation timings. NG feeding does not appear to merit recommendation within the initial 24 h, whereas NJ feeding is advisable within the corresponding timeframe following admission. These findings offer valuable insights for optimizing nutritional interventions in AP.
Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants will have a combined prescriptive and behavioral intervention- three guideline-advised strategies that may be synergistic in a subset of participants requiring knowledge, and needing goal setting and problem-solving skills. This approach is available in multispecialty, tertiary care obesity clinics.
The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
Patients with loss of HBsAg (spontaneously or under NA). This group will allow comparison of the HBsAg loss immuno-virological profile with that of patients with active infection and varying levels of HBsAg (groups 1-3 and 5) and aid in identifying of predictors of functional cure. The identification of determinants of HBV functional cure is fundamental and is comparable to investigations that have been carried out in HIV-infected "elite controllers".
PURPOSE:The titled composition, obtained by incorporating an N-long chain alkyloylsarcosinate having a metal selected from lithium, magnesium, nickel, tin, copper, zinc and aluminum as a base, and having foul breath inhibitory action. CONSTITUTION:A composition for oral cavity obtained by incorporating 0.05- 0.5wt% N-long chain alkyloylsarcosinate having two or more metals selected from lithium, magnesium, nickel, tin, copper, zinc and aliminum as a base, e.g. lauroylsarcosinate. The above-mentioned N-long chain alkyloylsarcosinate inhibits the ability of bacteria belonging to the genus Fusobacterium to generate foul breath which is a cause for generating the foul breath, and exhibits the foul breath inhibitory effect. A surfactant, e.g. nonionic, anionic or amphoteric surfactant, may be further incorporated in the above-mentioned composition and used as toothpaste, tooth wash, gingiva massage cream, etc.
Fibrotic skin diseases, such as keloids, are pathological results of aberrant tissue healing and are characterized by overgrowth of dermal fibroblasts. Remdesivir (RD), an antiviral drug, has been reported to have pharmacological activities in a wide range of fibrotic diseases. However, whether RD function on skin fibrosis remains unclear. Therefore, in our study, we explored the potential effect and mechanisms of RD on skin fibrosis both in vivo and in vitro. As expected, the results demonstrated that RD alleviated BLM-induced skin fibrosis and attenuates the gross weight of keloid tissues in vivo. Further studies suggested that RD suppressed fibroblast activation and autophagy both in vivo and in vitro. In addition, mechanistic research showed that RD attenuated fibroblasts activation by the TGF-β1/Smad signaling pathway and inhibited fibroblasts autophagy by the PI3K/Akt/mTOR signaling pathway. In summary, our results demonstrate therapeutic potential of RD for skin fibrosis in the future.
BACKGROUND: The use of an antibacterial envelope is cost-effective for patients at high risk of developing cardiac implantable electronic device (CIED) infection. The identification of these high-risk patients may be facilitated using a clinical risk score. The aim of the current study is to evaluate the PADIT score for identifying high-risk patients in patients undergoing a CIED procedure in a tertiary academic center.
METHODS: This was a retrospective single-center study of consecutive patients undergoing a CIED procedure between January 2016 and November 2021. Patients who received an antibacterial envelope were excluded from this study. The primary endpoint was hospitalization for a CIED infection in the first year after the procedure.
RESULTS: A total of 2333 CIED procedures were performed in the study period (mean age 61.6 ± 16.3 years, male sex 64.5%, previous CIED infection 1.7%, immunocompromised 5.4%). The median PADIT score was 4 (interquartile range, 2-6). CIED infection occurred in 10 patients (0.43%). The PADIT score had good discrimination in predicting major CIED infection (C-statistic 0.70; 95% confidence interval [CI] 0.54 to 0.86, P = 0.03). Using an optimal PADIT score cut-off value of 7, the risk of CIED infection was higher in the patients with a PADIT score of ≥ 7 in comparison to those with a lower PADIT score (1.23% vs. 0.26%, P = 0.02; odds ratio 4.8, 95% CI 1.4 to 16.6, P = 0.01).
CONCLUSIONS: The PADIT score is a clinically useful score for identifying patients at high risk of developing CIED infection. The use of an antibacterial envelope in these high-risk patients may be cost-effective.
One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
OBJECTIVE: Lamotrigine (LTG) an anticonvulsant drug with a dissociation constant (pKa: 5.7), suffers from enhanced blood plasma spike after each dose, when administered as fast release tablet. Being BCS class-II candidate and pH dependent solubility, development of release-controlled tablets of LTG is a major challenge. This investigation aims at designing the release-controlled tablet (RCT) formulation of LTG using a solid dispersion (SD) technique via addressing its solubility and release problems.
MATERIAL AND METHODS: RCT of LTG was fabricated using SD blend of Eudragit RL and Eudragit RS and PVP K-30 with different polymer blend ratio (1:5 and 1:7). The optimization of RCT of LTG was performed using D-optimal mixture design with three independent variables, three response variables, and one constraint. The dissolution rate was determined and data were then fitted to different mathematical models. Scanning electron microscopy (SEM) and X-ray diffraction (XRD) studies and tableting parameters were analyzed.
RESULT: In vitro studies of predicted optimized batches (POBs) have shown that drug release over a period of 12hours was 88.05±3.4% in media I, 86.10±3.7% in media II and 85.84±4.2% in media III. An in vitro kinetic model equating R2-value for all the tested models indicated that the first order and Higuchi release kinetics model were the most appropriate.
CONCLUSION: Based on the optimized formulation consisting of SD of LTG with Eudragit RL, Eudragit RS and PVP K-30, the release rate was consistently similar throughout the GI tract, regardless of the pH of the environment.
This study will be conducted at Zagazig University hospital. Laboratory work will be implemented at Immunology Research Laboratory at Microbiology and Immunology Department, Faculty of Medicine, Zagazig University. A representative sample will be drawn from healthcare workers (HCWs) at Zagazig University Hospital. Assessment of inclusion and exclusion criteria by history taking. Blood samples will be drawn from HCWs by direct venipuncture before the start of immunization and 14 days after immunization. The incidence of any adverse reactions after each immunization will be recorded. SARS-CoV-2 neutralizing antibodies will be detected by enzyme-linked immunosorbent assay.
The present invention addresses the problem of providing a pharmaceutical preparation composition which is a pharmaceutical preparation containing a polymerized camptothecin derivative produced by bonding a camptothecin derivative capable of associating in an aqueous solution thereof to form nano particle to a polymer carrier, and which has improved pharmaceutical stability. Particularly, the present invention addresses the problem of providing a pharmaceutical preparation capable of maintaining the nano particle-forming property thereof, which is an important factor, and having excellent storage stability. A pharmaceutical preparation which contains a block copolymer composed of a polyethylene glycol segment and a polyglutamic acid segment linked to each other, wherein the polyglutamic acid segment contains a glutamic acid unit having a camptothecin derivative bonded thereto. In an aqueous solution of the pharmaceutical preparation, associations can be formed. When the pharmaceutical preparation is prepared into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the aqueous solution has a pH value of 2.4 to 7.0. In the pharmaceutical preparation, the rate of change in the ability of forming the associations after the pharmaceutical preparation is stored at 40°C for 1 week under light-blocked conditions is 50% or less.
Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
Compositions and methods for making and using liposomal formulations of paclitaxel are disclosed. The liposomal paclitaxel formulations are used with treatment regimens for bladder cancer and both lower and upper tract urothelial cancer. Hence, the formulations are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include paclitaxel, lecithin, cholesterol, threonine, and glucose. (La presente invention concerne des compositions et des precedes de fabrication et d'utilisation de formulations liposomales de paclitaxel. Les formulations liposomales de paclitaxel sont utilisees avec des schemes therapeutiques pour le cancer de la vessie et le cancer des voies urotheliales des voies inferieures et superieures. Par consequent, les formulations sont appropriees pour trailer les cancers de la vessie par administration intravesicale et pour traiter les cancers de I'urothelium. Les formulations selon I'invention comprennent le paclitaxel, la lecithine, le cholesterol, la threonine et le glucose.)
NEW MATERIAL:The compound of formula I (n is 1-5; X is O or S; R<1> and R<2> are H, 1-4C alkyl or 1-4C hydroxyalkyl) and its salt. USE:A medicine. An antibacterial agent. It is a solid having dark red color, soluble in a number of organic solvents, exhibiting strong antibacterial activity against Gram-positive bacteria and acid-fast bacteria and having low toxicity. It can be used as a production raw material for novel rifamycin derivative of formula II having strong antibacterial activity. It is administered at a rate of 10mg-10g of the active component daily for adult. PREPARATION:The compound of formula I can be produced by reacting a rifamycin derivative of formula III with an amine of formula IV in an organic solvent such as methanol in the presence of a reducing agent such as sodium cyanoborohydride at room temperature for 30min - about 1 month, thereby effecting reductive amination reaction.
Arrhythmia is a major cardiac abnormality in fetuses. Therefore, early diagnosis of arrhythmia is clinically crucial. Pulsed-wave Doppler ultrasound is a commonly used diagnostic tool for fetal arrhythmia. Its key step for diagnosis involves identifying adjacent measurable cardiac cycles (MCCs). As cardiac activity is complex and the experience of sonographers is often varied, automation can improve user-independence and diagnostic-validity. However, arrhythmias pose several challenges for automation because of complex waveform variations, which can cause major localization bias and missed or false detection of MCCs. Filtering out non-MCC anomalies is difficult because of large intra-class and small inter-class variations between MCCs and non-MCCs caused by agnostic morphological waveform variations. Moreover, rare arrhythmia cases are insufficient for classification algorithms to adequately learn discriminative features. Using only normal cases for training, we propose a novel hierarchical online contrastive anomaly detection (HOCAD) framework for arrhythmia diagnosis during test time. The contribution of this study is three-fold. First, we develop a coarse-to-fine framework inspired by hierarchical diagnostic logic, which can refine localization and avoid missed detection of MCCs. Second, we propose an online learning-based contrastive anomaly detection with two new anomaly scores, which can adaptively filter out non-MCC anomalies on a single image during testing. With these complementary efforts, we precisely determine MCCs for correct measurements and diagnosis. Third, to the best of our knowledge, this is the first reported study investigating intelligent diagnosis of fetal arrhythmia on a large-scale and multi-center ultrasound dataset. Extensive experiments on 3850 cases, including 266 cases covering three typical types of arrhythmias, demonstrate the effectiveness of the proposed framework.
The present invention provides for an immunogenic analogue of a human TNF.alpha. protein, wherein said analogue comprises an immunogenized monomeric TNF.alpha. polypeptide or TNF.alpha. di- or trimer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the amino acid numbering setting out from the N-terminal valine in human TNF.alpha.. The invention also provides for a nucleic acid fragment encoding the analogue as well as to vectors and transformed cells useful in the preparation of the analogue. Also disclosed are methods of down-regulating TNF.alpha. in a subject in need thereof.